MHF Research Clinical Trials

MHF is currently enrolling patients in the following clinical trials. For more information contact Karen Larimer, Director of Research at
630.932.2165.

*NOTE: This is NOT a complete list of current studies

HEART FAILURE STUDIES

-A device study for patients in need of an internal cardioverter
defibrillator (ICD). The device combines the ICD with the ability to
monitor pressure in the heart

-A device study for patients with dilated cardiomyopathy, involving a
metal mesh net that surrounds and supports the heart

-A device study to collect and analyze pressures inside the heart in
order to help regulate medications and monitor fluid levels in the body.
This may prevent the need for hospitalization for congestive heart failure

-An inpatient study for patients hospitalized with decompensated heart
failure. This study compares an already FDA approved drug to placebo

-A device study to determine whether cardiac resynchronization therapy
(CRT) in combination with internal cardioverter defibrillator (CRT-D) can
stop or slow the development of heart failure and reduce death in people
who have early stages of heart failure

-A drug study to compare an investigational drug to placebo to determine
if people with heart failure live longer or do better on this drug

-A drug study to compare an investigational drug vs. placebo in patients
who require hospitalization for heart failure to determine the effects on
body weight and kidney function

 
CORONARY ARTERY DISEASE

-A registry study evaluating an investigational stent in patients with a
positive stress test or angina who have coronary artery disease requiring
intervention

-A drug is given at the time of a heart attack to determine if the patient
does better after the heart attack compared to someone receiving a
placebo

-A study for patients who receive a stent to determine if using 2 drugs to
block platelets for more than 1 year is better than stopping at the end of
1 year

PULMONARY HYPERTENSION

-This registry is coordinated to gather real-time information about patients
with Primary, Pulmonary Arterial Hypertension in an effort to understand
more about the disease, it’s characteristics, it’s course and responses to
current treatment. Patients consent to have their medical records reviewed
over a 5 year period with data reported to a central, electronic database for
analysis

-A drug study to evaluate if patients with PPAH do better on one or both drugs

ARRHYTHMIA

-A drug for patients who have had a shock from their defibrillator. This drug
is compared to placebo to see if shocks will not reoccur.

-A study using MRI to determine scar size after heart attack. Some pateints
will receive a defibrillator which may reduce occurrence of sudden death.